Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
genting is a gone case for now and may go below 2.60 in the next few months until more clarity on its GenM takeover in June. when there s no dividends for the rest of 2026, easily it could fall below rm2.30 n continue to rm2 in 2027. by that time, the boss would be happy to delist Genting Berhad at 2.35 instead of delisting GenM.
Mrs xlg, your later could be after June when there s more clarity on the privatization. if by then still now news and update, then it would definitely below 2.50. in saying this, there s still one more wildcard which is taurx. by June, there should be decision on the hmtm drug. if MHRA rejects it. then jialat, easily down below rm2.
in conclusion, if you enter now, you are looking at rm0.2-0.3 gain by June or you could at risk of losing 0.4-0.5 by June too if it down below rm2.50 due to all the negative news that I have stated.
the only positive news is taurx approval and the market could just react like in Oct and pushed the price up to 3.50 below dropping back again. but Taurx should be able to hold genting above rm3 for years to come due to additional 1 billion income from the drug sales.